{"id":51465,"date":"2022-12-01T17:02:28","date_gmt":"2022-12-01T16:02:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/novel-antibody-therapies-market-2035-researchandmarkets-com\/"},"modified":"2022-12-01T17:02:28","modified_gmt":"2022-12-01T16:02:28","slug":"novel-antibody-therapies-market-2035-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/novel-antibody-therapies-market-2035-researchandmarkets-com\/","title":{"rendered":"Novel Antibody Therapies Market, 2035 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Novel Antibody Therapies Market: Distribution by Type of Novel Antibody, Target Indication, Type of Therapy, Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe ‘Novel Antibody Therapies Market, 2022-2035’ report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the novel antibody therapies in the treatment of various diseases.\n<\/p>\n

\nThe study presents an in-depth analysis, highlighting the diverse capabilities of players engaged in this domain, across different geographies.\n<\/p>\n

\nOne of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated with novel antibody therapies market in the mid to long term. Based on parameters, such as historical sales, target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the likely evolution of the market for the period 2022-2035.\n<\/p>\n

\nOur year wise projections of the current and forecasted opportunity within the novel antibody therapies market have further been segmented across type of novel antibody (immunocytokines, immunotoxins, and radioisotope immunoconjugates), target indication (acute myeloid leukemia, bladder cancer, diffuse large b-cell lymphoma, graft-versus-host disease, melanoma prostate cancer, and soft-tissue sarcoma), type of therapy (Combination Therapy and Monotherapy), route of administration (intratumoral, intravenous and intravesical), key geographical regions (North America, Europe and Asia-Pacific).\n<\/p>\n

\nIn order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.\n<\/p>\n

\nAmidst the recent initiatives undertaken to develop more targeted anti-cancer therapies, novel antibody therapies have emerged to be one of the most suitable option, having demonstrated the capability to selectively target and eliminate tumor cells. The novel antibody therapies include different classes of antibodies, which are capable of killing or inhibiting disease-causing agents.\n<\/p>\n

\nMultiple antibody formats have been engineered to enhance therapeutic efficacy and target proteins that are expressed on the surface of the affected cells. This has opened a new target space for the development of antibody therapeutics and techniques, facilitating tools to uniquely distinguish malignantly transformed cells from regular cells. Various novel antibody therapies such as immuocytokines, immunotoxins, radioimmunoconjugates and intrabodies are being investigated as a therapeutic modality across multiple clinical trials, particularly as anti-cancer agents.\n<\/p>\n

\nTill date, six novel antibody therapies, including Adcetris (mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, T-cell lymphoma and Hodgkin’s disease), Elzonris (Blastic plasmacytoid dendritic cell neoplasm) Lumoxiti (Hairy cell leukemia), PluvictoT (Prostate cancer), VicineumT (Bladder cancer) and Zevalin (Lymphoma) have so far been evaluated and approved for various oncological disorders.\n<\/p>\n

\nIn addition, more than 130 novel antibody therapies are being evaluated in various preclinical and clinical stages. Currently, more than 50 companies and academic \/ research institutes are engaged in the development of novel antibody therapies with enhanced efficacy and several promising leads are anticipated to be commercially launched over the coming decade.\n<\/p>\n

\nOver 4,500 patents related to novel antibodies have been recently filed \/ granted, demonstrating the innovation and continuous research efforts in this domain. In addition, multiple collaborations have been inked between industry \/ academic stakeholders to advance the development of various pipeline molecules.\n<\/p>\n

\nMoreover, with the active involvement of big pharma players as well as new entrants, the development pipeline of the novel antibody therapies is likely to expand further. Driven by the growing interest of various stakeholders and encouraging clinical research results, the novel antibody therapies market is anticipated to witness steady growth over the coming years.\n<\/p>\n

\nKey Questions Answered<\/strong>\n<\/p>\n